Personalized vaccine with chemotherapy for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with glioblastoma (a fast-growing brain tumor) and have completed standard treatment (surgery plus chemo-radiation).
- Your tumor is the type that does not have IDH1 or IDH2 gene mutations (a test done on your tumor tissue).
- You are in generally good health, with a performance score of at least 50 (you can do some daily activities).
- You can provide tissue and blood samples and have good veins for blood draws.
- You are willing to use contraception (if applicable) during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.